

Vijay Ramaswamy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5533966/publications.pdf>

Version: 2024-02-01

279
papers

18,616
citations

21215

62
h-index

16791

127
g-index

290
all docs

290
docs citations

290
times ranked

19389
citing authors

#	ARTICLE	IF	CITATIONS
1	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. <i>Neuro-Oncology</i> , 2022, 24, 153-165.	0.6	28
2	Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 116-128.	3.2	8
3	Radiomic signatures of posterior fossa ependymoma: Molecular subgroups and risk profiles. <i>Neuro-Oncology</i> , 2022, 24, 986-994.	0.6	8
4	Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29633.	0.8	6
5	A novel central nervous system embryonal tumor successfully treated with multimodal therapy highlights limitation of methylation-based tumor classification. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29520.	0.8	1
6	MRI Radiogenomics of Pediatric Medulloblastoma: A Multicenter Study. <i>Radiology</i> , 2022, 304, 406-416.	3.6	27
7	Building the ecosystem for pediatric neuro-oncology care in Pakistan: Results of a 7-year long twinning program between Canada and Pakistan. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29726.	0.8	4
8	Recurrent ACVR1 mutations in posterior fossa ependymoma. <i>Acta Neuropathologica</i> , 2022, 144, 373-376.	3.9	7
9	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. <i>Neuro-Oncology</i> , 2022, 24, i107-i107.	0.6	1
10	PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study. <i>Neuro-Oncology</i> , 2022, 24, i158-i158.	0.6	0
11	MEDB-07. Long-term medical and functional outcomes of medulloblastoma survivors: a population-based, matched cohort study. <i>Neuro-Oncology</i> , 2022, 24, i105-i105.	0.6	0
12	MEDB-43. Development of a bioinformatics pipeline for identification of differential DNA methylation events associated with medulloblastoma relapse. <i>Neuro-Oncology</i> , 2022, 24, i115-i115.	0.6	0
13	MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?. <i>Neuro-Oncology</i> , 2022, 24, i117-i117.	0.6	0
14	Long-term medical and functional outcomes of medulloblastoma survivors: A population-based, matched cohort study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10053-10053.	0.8	0
15	P.139 Pediatric posterior fossa ependymoma recurrence in a molecularly defined cohort – Clinical, demographic, and surgical factors associated with outcome. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, S43-S43.	0.3	1
16	Long-term medical and functional outcomes of ependymoma survivors: A population-based, matched cohort study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10054-10054.	0.8	0
17	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2042-2042.	0.8	2
18	Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression. <i>Communications Biology</i> , 2022, 5, .	2.0	8

#	ARTICLE	IF	CITATIONS
19	The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	16
20	Intellectual changes after radiation for children with brain tumors: which brain structures are most important?. <i>Neuro-Oncology</i> , 2021, 23, 487-497.	0.6	16
21	Radiation-induced intracranial aneurysm presenting with acute hemorrhage in a child treated for medulloblastoma. <i>Child's Nervous System</i> , 2021, 37, 1387-1389.	0.6	2
22	Next-Generation Profiling of Medulloblastoma: Old Drugs Are an Elegant Weapon in a Civilized Age. <i>Cancer Research</i> , 2021, 81, 264-265.	0.4	0
23	Artificial intelligence for automatic cerebral ventricle segmentation and volume calculation: a clinical tool for the evaluation of pediatric hydrocephalus. <i>Journal of Neurosurgery: Pediatrics</i> , 2021, 27, 131-138.	0.8	17
24	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021, 23, 1360-1370.	0.6	46
25	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	0.8	40
26	Medulloblastoma (cross)talk through extracellular vesicles. <i>Neuro-Oncology</i> , 2021, 23, 527-529.	0.6	1
27	Piecing together the Pediatric Brain Tumor Puzzle. <i>Trends in Genetics</i> , 2021, 37, 204-206.	2.9	2
28	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	5.8	47
29	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. <i>Cancer Discovery</i> , 2021, 11, 2230-2247.	7.7	39
30	Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?. <i>Neuro-Oncology</i> , 2021, 23, 1627-1628.	0.6	3
31	Machine Assist for Pediatric Posterior Fossa Tumor Diagnosis: A Multinational Study. <i>Neurosurgery</i> , 2021, 89, 892-900.	0.6	8
32	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	3.9	34
33	Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?. <i>Journal of Neuro-Oncology</i> , 2021, 155, 63-70.	1.4	6
34	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 800-813.	2.7	12
35	Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children. <i>Journal of Clinical Oncology</i> , 2021, 39, 3813-3821.	0.8	11
36	Hearing loss and intellectual outcome in children treated for embryonal brain tumors: Implications for young children treated with radiation sparing approaches. <i>Cancer Medicine</i> , 2021, 10, 7111-7125.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Ventricular size determination and management of ventriculomegaly and hydrocephalus in patients with diffuse intrinsic pontine glioma: an institutional experience. <i>Journal of Neurosurgery</i> , 2021, 135, 1139-1145.	0.9	3
38	Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country. <i>JCO Global Oncology</i> , 2021, 7, 1442-1453.	0.8	12
39	Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. <i>JAMA Oncology</i> , 2021, 7, 1806.	3.4	22
40	Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	11
41	60: Re-Evaluating Surgery and Re-Irradiation for Locally Recurrent Pediatric Ependymoma – A Multi-Institutional Study. <i>Radiotherapy and Oncology</i> , 2021, 163, S28.	0.3	0
42	Re-evaluating surgery and re-irradiation for locally recurrent pediatric ependymoma – a multi-institutional study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab158.	0.4	5
43	Molecular and clinical correlates of medulloblastoma subgroups: A narrative review. <i>Glioma (Mumbai, India)</i> , 2021, 4, 92.	0.0	2
44	Molecular correlates of cerebellar mutism syndrome in medulloblastoma. <i>Neuro-Oncology</i> , 2020, 22, 290-297.	0.6	21
45	Less treatment for Wing less medulloblastoma: germline data re-emphasize this. <i>Neuro-Oncology</i> , 2020, 22, 7-9.	0.6	5
46	The molecular biology of medulloblastoma metastasis. <i>Brain Pathology</i> , 2020, 30, 691-702.	2.1	25
47	Rare IDH1 variants are common in pediatric hemispheric diffuse astrocytomas and frequently associated with Li-Fraumeni syndrome. <i>Acta Neuropathologica</i> , 2020, 139, 795-797.	3.9	7
48	Minimizing General Anesthetic Use in Pediatric Radiation Therapy. <i>Practical Radiation Oncology</i> , 2020, 10, e159-e165.	1.1	14
49	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , 2020, 139, 223-241.	3.9	65
50	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. <i>Cancer Medicine</i> , 2020, 9, 447-459.	1.3	11
51	Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 454-461.	0.8	143
52	Indolent course of brainstem tumors with K27Mê€H3.3 mutation. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28102.	0.8	4
53	An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. <i>Nature Communications</i> , 2020, 11, 3627.	5.8	21
54	European genetic ancestry associated with risk of childhood ependymoma. <i>Neuro-Oncology</i> , 2020, 22, 1637-1646.	0.6	16

#	ARTICLE	IF	CITATIONS
55	Reirradiation for recurrent craniopharyngioma. <i>Advances in Radiation Oncology</i> , 2020, 5, 1305-1310.	0.6	3
56	Causes of death in pediatric neuro-oncology: the sickkids experience from 2000 to 2017. <i>Journal of Neuro-Oncology</i> , 2020, 149, 181-189.	1.4	10
57	Bevacizumab for pediatric radiation necrosis. <i>Neuro-Oncology Practice</i> , 2020, 7, 409-414.	1.0	9
58	Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 173.	2.4	15
59	Chloride intracellular channel 1 cooperates with potassium channel EAG2 to promote medulloblastoma growth. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	24
60	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. <i>Acta Neuropathologica</i> , 2020, 140, 765-776.	3.9	23
61	Deep Learning for Pediatric Posterior Fossa Tumor Detection and Classification: A Multi-Institutional Study. <i>American Journal of Neuroradiology</i> , 2020, 41, 1718-1725.	1.2	31
62	Neurotrophin Signaling in Medulloblastoma. <i>Cancers</i> , 2020, 12, 2542.	1.7	25
63	Canadian Pediatric Neuro-Oncology Standards of Practice. <i>Frontiers in Oncology</i> , 2020, 10, 593192.	1.3	13
64	Treatment response of CNS high-grade neuroepithelial tumors with MN1 alteration. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28627.	0.8	5
65	54: Re-Irradiation for Recurrent Craniopharyngioma. <i>Radiotherapy and Oncology</i> , 2020, 150, S26-S27.	0.3	0
66	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. <i>JCO Precision Oncology</i> , 2020, 4, 561-571.	1.5	62
67	Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy. <i>Journal of Pathology</i> , 2020, 251, 249-261.	2.1	53
68	Reply to S.A. Milgrom et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 2212-2213.	0.8	1
69	Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28228.	0.8	17
70	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	3.3	24
71	Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. <i>Neuro-Oncology</i> , 2020, 22, 1873-1881.	0.6	12
72	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. <i>Neuro-Oncology</i> , 2020, 22, 773-784.	0.6	44

#	ARTICLE	IF	CITATIONS
73	HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma. Journal of Molecular Neuroscience, 2020, 70, 981-992.	1.1	21
74	Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. Journal of Neuropathology and Experimental Neurology, 2020, 79, 437-447.	0.9	19
75	The AHR pathway represses TGF β 2-SMAD3 signalling and has a potent tumour suppressive role in SHH medulloblastoma. Scientific Reports, 2020, 10, 148.	1.6	22
76	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell, 2020, 37, 569-583.e5.	7.7	244
77	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology, 2020, 22, 1474-1483.	0.6	39
78	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nature Medicine, 2020, 26, 720-731.	15.2	141
79	Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. Cell, 2020, 181, 1329-1345.e24.	13.5	79
80	MBRS-54. POOR SURVIVAL IN REPLICATION REPAIR DEFICIENT HYPERMUTANT MEDULLOBLASTOMA AND CNS EMBRYONAL TUMORS: A REPORT FROM THE INTERNATIONAL RRD CONSORTIUM. Neuro-Oncology, 2020, 22, iii407-iii407.	0.6	1
81	EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDREN'S HAEMATOLOGY/ONCOLOGY GROUP. Neuro-Oncology, 2020, 22, iii315-iii315.	0.6	0
82	PATH-20. METHYLATION ARRAY PROFILING OF PEDIATRIC BRAIN TUMORS; SINGLE CENTRE EXPERIENCE. Neuro-Oncology, 2020, 22, iii428-iii428.	0.6	0
83	RARE-02.RE-IRRADIATION FOR RECURRENT CRANIOPHARYNGIOMA. Neuro-Oncology, 2020, 22, iii442-iii442.	0.6	0
84	QOL-01. LONGITUDINAL COMPARISON OF NEUROCOGNITIVE TRAJECTORIES IN PEDIATRIC MEDULLOBLASTOMA PATIENTS TREATED WITH PROTON VERSUS PHOTON RADIOTHERAPY. Neuro-Oncology, 2020, 22, iii431-iii431.	0.6	0
85	IMG-13. MRI-BASED RADIOMICS PROGNOSTIC MARKERS OF POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology, 2020, 22, iii357-iii357.	0.6	0
86	HGG-20. DIAGNOSTIC AND BIOLOGICAL ROLE OF METHYLATION PATTERNS IN REPLICATION REPAIR DEFICIENT HIGH GRADE GLIOMAS. Neuro-Oncology, 2020, 22, iii347-iii348.	0.6	0
87	DIPG-72. LONG-TERM SURVIVAL OF A CLASSIC DIFFUSE INTRINSIC PONTINE GLIOMA TREATED WITH NIMOTUZUMAB. Neuro-Oncology, 2020, 22, iii301-iii301.	0.6	0
88	IMG-22. A DEEP LEARNING MODEL FOR AUTOMATIC POSTERIOR FOSSA PEDIATRIC BRAIN TUMOR SEGMENTATION: A MULTI-INSTITUTIONAL STUDY. Neuro-Oncology, 2020, 22, iii359-iii359.	0.6	0
89	MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE. Neuro-Oncology, 2020, 22, iii400-iii400.	0.6	0
90	RONC-03. NEUROCOGNITIVE CHANGES AFTER RADIATION FOR PEDIATRIC BRAIN TUMOURS: WHICH BRAIN SUBSTRUCTURES ARE MOST IMPORTANT?. Neuro-Oncology, 2020, 22, iii456-iii456.	0.6	0

#	ARTICLE	IF	CITATIONS
91	QOL-09. WHOLE-BRAIN WHITE MATTER NETWORK CONNECTIVITY IS DISRUPTED BY PEDIATRIC BRAIN TUMOR TREATMENT. <i>Neuro-Oncology</i> , 2020, 22, iii432-iii432.	0.6	1
92	MBRS-66. COST-EFFECTIVE METHOD TO INCORPORATE MOLECULAR CLASSIFICATION OF MEDULLOBLASTOMA INTO A LATIN-AMERICAN CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii409-iii410.	0.6	1
93	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. <i>Neuro-Oncology</i> , 2020, 22, iii377-iii377.	0.6	0
94	EPEN-50. THE MANAGEMENT AND TREATMENT OF PEDIATRIC SPINAL CORD EPENDYMOMA: RESULTS FROM A COLLABORATIVE INTERNATIONAL MULTI-INSTITUTIONAL REVIEW. <i>Neuro-Oncology</i> , 2020, 22, iii317-iii318.	0.6	0
95	MBCL-08. INTEGRATIVE MOLECULAR ANALYSIS OF PATIENT-MATCHED DIAGNOSTIC AND RELAPSED MEDULLOBLASTOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii389-iii389.	0.6	0
96	Genetic Basis and Classification of Cerebral Neoplasms. , 2020, , 1775-1791.		0
97	Management and Treatment of Pediatric Spinal Cord Ependymoma: Results from an International Multi-Institutional Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e235-e236.	0.4	0
98	Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma. <i>Frontiers in Pharmacology</i> , 2019, 10, 698.	1.6	15
99	Redefining Ventricular Target Volume in Germinoma: Is Inclusion of Temporal Horns Necessary?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 852-858.	0.4	7
100	MEDU-04. AN OTX2-PAX GENE NETWORK REGULATES GROUP 3 MEDULLOBLASTOMA DIFFERENTIATION AND TUMOR GROWTH. <i>Neuro-Oncology</i> , 2019, 21, ii103-ii104.	0.6	0
101	Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. <i>Journal of Neuro-Oncology</i> , 2019, 145, 107-114.	1.4	18
102	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. <i>Nature Communications</i> , 2019, 10, 4343.	5.8	200
103	Repeat irradiation for children with supratentorial high-grade glioma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27881.	0.8	14
104	Reply to "Assembling the brain trust: the multidisciplinary imperative in neuro-oncology". <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 522-523.	12.5	0
105	Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma. <i>BMC Cancer</i> , 2019, 19, 571.	1.1	40
106	IMMU-03. TUMOR NECROSIS FACTOR OVERCOMES IMMUNE EVASION IN P53-MUTANT MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii93-ii93.	0.6	1
107	GENE-14. UNIQUE MOLECULAR AND CLINICAL FEATURES OF LI-FRAUMENI SYNDROME ASSOCIATED BRAIN TUMOURS. <i>Neuro-Oncology</i> , 2019, 21, ii84-ii84.	0.6	1
108	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. <i>Acta Neuropathologica</i> , 2019, 138, 309-326.	3.9	180

#	ARTICLE	IF	CITATIONS
109	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. <i>Nature</i> , 2019, 572, 67-73.	13.7	293
110	Effective and safe tumor inhibition using vinblastine in medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27694.	0.8	7
111	Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 974-983.	0.8	154
112	Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas. <i>Acta Neuropathologica Communications</i> , 2019, 7, 52.	2.4	17
113	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	12.5	540
114	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. <i>Cancer</i> , 2019, 125, 1867-1876.	2.0	49
115	MEDU-26. LATENT SOX9-POSITIVE CELLS RESPONSIBLE FOR MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE. <i>Neuro-Oncology</i> , 2019, 21, ii108-ii109.	0.6	0
116	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. <i>Neuro-Oncology</i> , 2019, 21, ii102-ii102.	0.6	0
117	MEDU-40. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii111-ii112.	0.6	0
118	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. <i>Nature</i> , 2019, 574, 707-711.	13.7	129
119	101 Re-Irradiation for Children with Recurrent Supratentorial High-Grade Glioma. <i>Radiotherapy and Oncology</i> , 2019, 139, S45.	0.3	0
120	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 547-557.	0.6	32
121	PPAR and GST polymorphisms may predict changes in intellectual functioning in medulloblastoma survivors. <i>Journal of Neuro-Oncology</i> , 2019, 142, 39-48.	1.4	21
122	BM11 is a therapeutic target in recurrent medulloblastoma. <i>Oncogene</i> , 2019, 38, 1702-1716.	2.6	20
123	Bioinformatic Strategies for the Genomic and Epigenomic Characterization of Brain Tumors. <i>Methods in Molecular Biology</i> , 2019, 1869, 37-56.	0.4	4
124	MR Imaging-Based Radiomic Signatures of Distinct Molecular Subgroups of Medulloblastoma. <i>American Journal of Neuroradiology</i> , 2019, 40, 154-161.	1.2	87
125	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. <i>Cell</i> , 2018, 172, 1050-1062.e14.	13.5	85
126	Characterization of a novel OTX-driven stem cell program in Group 3 and Group 4 medulloblastoma. <i>Molecular Oncology</i> , 2018, 12, 495-513.	2.1	16

#	ARTICLE	IF	CITATIONS
127	Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies. Annual Review of Neuroscience, 2018, 41, 207-232.	5.0	85
128	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. Clinical Cancer Research, 2018, 24, 1355-1363.	3.2	24
129	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. Pediatric Blood and Cancer, 2018, 65, e26988.	0.8	51
130	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature, 2018, 553, 101-105.	13.7	170
131	MRI Characteristics of Primary Tumors and Metastatic Lesions in Molecular Subgroups of Pediatric Medulloblastoma: A Single-Center Study. American Journal of Neuroradiology, 2018, 39, 949-955.	1.2	27
132	miR miR on the wall, whoâ€™s the most malignant medulloblastoma miR of them all?. Neuro-Oncology, 2018, 20, 313-323.	0.6	15
133	Adolescents and young adults with brain tumors in the context of molecular advances in neuroâ€™ncology. Pediatric Blood and Cancer, 2018, 65, e26861.	0.8	29
134	Differential patterns of metastatic dissemination across medulloblastoma subgroups. Journal of Neurosurgery: Pediatrics, 2018, 21, 145-152.	0.8	39
135	Review of molecular classification and treatment implications of pediatric brain tumors. Current Opinion in Pediatrics, 2018, 30, 3-9.	1.0	38
136	PDTM-28. THE CONTRIBUTION OF PAX GENES AS NOVEL TUMOR SUPPRESSORS IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, vi209-vi209.	0.6	0
137	EPEN-23. MOLECULAR HETEROGENEITY AMONG PEDIATRIC POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology, 2018, 20, i77-i78.	0.6	0
138	MBRS-14. REGULATION OF MEDULLOBLASTOMA IMMUNOGENICITY BY TP53 AND TNF ALPHA. Neuro-Oncology, 2018, 20, i131-i131.	0.6	0
139	LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS. Neuro-Oncology, 2018, 20, i106-i106.	0.6	0
140	RTHP-34. CRANIOSPINAL IRRADIATION (CSI) AS PART OF RE-IRRADIATION (RT2) FOR CHILDREN WITH RECURRENT INTRACRANIAL EPENDYMOMA. Neuro-Oncology, 2018, 20, vi232-vi232.	0.6	1
141	EPEN-28. HETEROGENEITY WITHIN THE PFB EPENDYMOMA SUBGROUP. Neuro-Oncology, 2018, 20, i79-i79.	0.6	0
142	EPEN-31. SUBGROUP SPECIFIC LONG-TERM SURVIVAL AND NEUROCOGNITIVE OUTCOMES IN POSTERIOR FOSSA EPENDYMOMA (PFE). Neuro-Oncology, 2018, 20, i79-i79.	0.6	0
143	PDTM-46. POLIOVIRUS RECEPTOR (CD155) EXPRESSION IN PEDIATRIC BRAIN TUMORS MEDIATES ONCOLYSIS OF MEDULLOBLASTOMA AND PLEOMORPHIC XANTHOASTROCYTOMA. Neuro-Oncology, 2018, 20, vi213-vi213.	0.6	0
144	TMOD-35. CAN RARE SOX9-POSITIVE CELLS INCITE MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE?. Neuro-Oncology, 2018, 20, vi276-vi276.	0.6	0

#	ARTICLE	IF	CITATIONS
145	GENE-21. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?. <i>Neuro-Oncology</i> , 2018, 20, vi107-vi107.	0.6	0
146	LGG-60. THE GENETIC LANDSCAPE OF PEDIATRIC LOW-GRADE GLIOMAS: INCIDENCE, PROGNOSIS AND RESPONSE TO THERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	0.6	1
147	PDTM-21. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi208-vi208.	0.6	1
148	Pediatric Brain Tumor Genetics: What Radiologists Need to Know. <i>Radiographics</i> , 2018, 38, 2102-2122.	1.4	75
149	Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. <i>Acta Neuropathologica Communications</i> , 2018, 6, 134.	2.4	74
150	Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. <i>Nature Communications</i> , 2018, 9, 4121.	5.8	36
151	18 Peroxiredoxin1 is a therapeutic target in group-3 medulloblastoma. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, S16-S16.	0.3	0
152	Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. <i>Science Signaling</i> , 2018, 11, .	1.6	59
153	Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. <i>Cancer Cell</i> , 2018, 34, 379-395.e7.	7.7	104
154	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	0.6	0
155	The clinical importance of medulloblastoma extent of resection: a systematic review. <i>Journal of Neuro-Oncology</i> , 2018, 139, 523-539.	1.4	43
156	CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. <i>Cancer Research</i> , 2018, 78, 4745-4759.	0.4	31
157	Clinical and pre-clinical utility of genomics in medulloblastoma. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 633-647.	1.4	13
158	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	3.9	86
159	DEV-17. WHO ARE THE HIGH RISK MEDULLOBLASTOMA SUBGROUPS IN JORDAN?. <i>Neuro-Oncology</i> , 2018, 20, i48-i48.	0.6	0
160	Infant medulloblastoma "learning new lessons from old strata. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 659-660.	12.5	15
161	CAR T cells for childhood diffuse midline gliomas. <i>Nature Medicine</i> , 2018, 24, 534-535.	15.2	3
162	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology</i> , The, 2018, 19, 785-798.	5.1	268

#	ARTICLE	IF	CITATIONS
163	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. <i>Acta Neuropathologica</i> , 2018, 136, 211-226.	3.9	199
164	Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 696-702.	0.9	38
165	Genetic Basis and Classification of Cerebral Neoplasms. , 2018, , 1-21.		1
166	Who are the high risk medulloblastoma subgroups in Jordan?. <i>Journal of Clinical Oncology</i> , 2018, 36, e22506-e22506.	0.8	0
167	The clinical significance of equivocal findings on spinal MRI in children with medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26472.	0.8	9
168	Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788.	9.4	112
169	Prognostic relevance of miR-124 and its target TP53INP1 in pediatric ependymoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 639-650.	1.5	16
170	H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. <i>Child's Nervous System</i> , 2017, 33, 1047-1051.	0.6	46
171	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	7.7	836
172	Can telomerase activity be unleashed to refine prognosis within ependymoma subgroups?. <i>Neuro-Oncology</i> , 2017, 19, 1149-1151.	0.6	0
173	The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival. <i>Neuro-Oncology</i> , 2017, 19, 1217-1227.	0.6	53
174	Disrupting the CD47-SIRP α anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	306
175	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	13.5	596
176	Drain the swamp to beat glioma. <i>Nature</i> , 2017, 549, 460-461.	13.7	4
177	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	13.7	787
178	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. <i>Acta Neuropathologica</i> , 2017, 134, 705-714.	3.9	168
179	Pontine Infantile Glioma Simplified. <i>Cancer Cell</i> , 2017, 32, 548-549.	7.7	1
180	Integrating RNA sequencing into neuro-oncology practice. <i>Translational Research</i> , 2017, 189, 93-104.	2.2	10

#	ARTICLE	IF	CITATIONS
181	Why it's time for a change in the management of adolescent and adult medulloblastoma. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 207-213.	0.6	0
182	A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote Sonic Hedgehog medulloblastoma. <i>Oncogene</i> , 2017, 36, 5969-5984.	2.6	42
183	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017, 133, 5-12.	3.9	271
184	Early diffusion restriction of white matter in infants with small subdural hematomas is associated with delayed atrophy. <i>Child's Nervous System</i> , 2017, 33, 289-295.	0.6	2
185	Current therapy and the evolving molecular landscape of paediatric ependymoma. <i>European Journal of Cancer</i> , 2017, 70, 34-41.	1.3	63
186	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	0.8	232
187	Medulloblastoma: From Myth to Molecular. <i>Journal of Clinical Oncology</i> , 2017, 35, 2355-2363.	0.8	129
188	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma. <i>Journal of Clinical Oncology</i> , 2017, 35, 10503-10503.	0.8	0
189	Neurocognitive outcome in children with sensorineural hearing loss after treatment of malignant embryonal brain tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2029-2029.	0.8	0
190	RA-10SUBTLE FINDINGS ON SPINAL MRIs IN CHILDREN NEWLY DIAGNOSED WITH MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, iii166.5-iii167.	0.6	0
191	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	7.7	191
192	Treatment implications of posterior fossa ependymoma subgroups. <i>Chinese Journal of Cancer</i> , 2016, 35, 93.	4.9	21
193	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , 2016, 131, 821-831.	3.9	478
194	WIP1 modulates responsiveness to Sonic Hedgehog signaling in neuronal precursor cells and medulloblastoma. <i>Oncogene</i> , 2016, 35, 5552-5564.	2.6	23
195	Old chemotherapy makes a comeback: dual alkylator therapy for pediatric high-grade glioma. <i>Neuro-Oncology</i> , 2016, 18, 1333-1334.	0.6	6
196	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4161-4170.	0.8	72
197	Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1527-1534.	0.8	94
198	Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3537-3543.	0.8	157

#	ARTICLE	IF	CITATIONS
199	Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in TP53-Associated Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2016, 34, 3697-3704.	0.8	33
200	Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2038-2041.	0.8	57
201	PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. <i>Cancer Research</i> , 2016, 76, 4708-4719.	0.4	107
202	Proton beam therapy for medulloblastoma. <i>Lancet Oncology</i> , The, 2016, 17, e173-e174.	5.1	2
203	MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. <i>BMC Cancer</i> , 2016, 16, 115.	1.1	17
204	Medulloblastoma in adults: they're not just big kids. <i>Neuro-Oncology</i> , 2016, 18, 895-897.	0.6	23
205	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	0.8	160
206	Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. <i>Cancer</i> , 2016, 122, 1261-1269.	2.0	109
207	Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. <i>Neuro-Oncology</i> , 2016, 18, 291-297.	0.6	112
208	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	13.7	266
209	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. <i>Journal of Clinical Oncology</i> , 2016, 34, 2206-2211.	0.8	692
210	Fall of the Optical Wall: Freedom from the Tyranny of the Microscope Improves Glioma Risk Stratification. <i>Cancer Cell</i> , 2016, 29, 137-138.	7.7	9
211	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	5.1	274
212	p53 and Medulloblastoma. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026278.	2.9	29
213	Low Grade Gliomas in Children. <i>Journal of Child Neurology</i> , 2016, 31, 517-522.	0.7	41
214	Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10509-10509.	0.8	3
215	Norrin/Frizzled4 signalling in the preneoplastic niche blocks medulloblastoma initiation. <i>ELife</i> , 2016, 5, .	2.8	21
216	Re-irradiation for relapsed paediatric ependymoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10565-10565.	0.8	1

#	ARTICLE	IF	CITATIONS
217	Imaging of metastatic medulloblastoma in the molecular era.. Journal of Clinical Oncology, 2016, 34, e22003-e22003.	0.8	0
218	Failure of diffusion weighted MRI to detect severe hypoxic-ischemic encephalopathy in a child. Journal of Pediatric Neurology, 2015, 08, 231-235.	0.0	0
219	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	7.7	933
220	Fingering the Correct Culprit: NonRANDOM Target Selection for Therapy of Neuroblastoma. Trends in Cancer, 2015, 1, 213-215.	3.8	0
221	Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathologica, 2015, 129, 449-457.	3.9	80
222	<i>BRAF</i> Mutation and <i>CDKN2A</i> Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1015-1022.	0.8	244
223	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	3.2	84
224	Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery. Journal of Neurosurgery: Pediatrics, 2015, 15, 236-242.	0.8	48
225	Pediatric cancer genomics, a play rather than a portrait. Nature Genetics, 2015, 47, 851-852.	9.4	3
226	Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas. Journal of Neurosurgery: Pediatrics, 2015, 16, 126-133.	0.8	27
227	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clinical Cancer Research, 2015, 21, 3750-3758.	3.2	40
228	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nature Neuroscience, 2015, 18, 1236-1246.	7.1	74
229	The Amazing and Deadly Glioma Race. Cancer Cell, 2015, 28, 275-277.	7.7	11
230	Posterior fossa ependymoma: current insights. Child's Nervous System, 2015, 31, 1699-1706.	0.6	29
231	Posterior fossa tumors in children: developmental anatomy and diagnostic imaging. Child's Nervous System, 2015, 31, 1661-1676.	0.6	63
232	Genetic and molecular alterations across medulloblastoma subgroups. Journal of Molecular Medicine, 2015, 93, 1075-1084.	1.7	51
233	Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. Cancer Research, 2015, 75, 134-146.	0.4	51
234	Basic Science of Pediatric Brain Tumors. , 2015, , 59-67.		1

#	ARTICLE	IF	CITATIONS
235	A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. <i>Oncotarget</i> , 2015, 6, 2709-2724.	0.8	24
236	Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes. <i>Oncotarget</i> , 2015, 6, 38881-38900.	0.8	22
237	Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. <i>Acta Neuropathologica</i> , 2014, 128, 863-877.	3.9	34
238	An epigenetic therapy for diffuse intrinsic pontine gliomas. <i>Nature Medicine</i> , 2014, 20, 1378-1379.	15.2	25
239	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 174.	2.4	37
240	Can miRNA-based real-time PCR be used to classify medulloblastomas?. <i>CNS Oncology</i> , 2014, 3, 173-175.	1.2	2
241	Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1190-1194.	0.8	42
242	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014, 506, 445-450.	13.7	521
243	MRI Surrogates for Molecular Subgroups of Medulloblastoma. <i>American Journal of Neuroradiology</i> , 2014, 35, 1263-1269.	1.2	257
244	The G protein β subunit $G\beta$ is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. <i>Nature Medicine</i> , 2014, 20, 1035-1042.	15.2	110
245	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	0.8	263
246	Advances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumors. <i>F1000prime Reports</i> , 2014, 6, 56.	5.9	13
247	Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 107-115.	0.8	39
248	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. <i>Acta Neuropathologica</i> , 2013, 125, 913-916.	3.9	244
249	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 125, 373-384.	3.9	169
250	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	5.1	307
251	Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children. <i>Cancer Research</i> , 2013, 73, 6734-6744.	0.4	79
252	Inflammasome induction in Rasmussen's encephalitis: cortical and associated white matter pathogenesis. <i>Journal of Neuroinflammation</i> , 2013, 10, 152.	3.1	55

#	ARTICLE	IF	CITATIONS
253	Canonical $TGF\beta^2$ Pathway Activity Is a Predictor of SHH-Driven Medulloblastoma Survival and Delineates Putative Precursors in Cerebellar Development. <i>Brain Pathology</i> , 2013, 23, 178-191.	2.1	26
254	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. <i>Child's Nervous System</i> , 2013, 29, 1253-1262.	0.6	12
255	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	3.9	146
256	Medulloblastoma molecular dissection. <i>Current Opinion in Oncology</i> , 2013, 25, 674-681.	1.1	54
257	In Reply. <i>Oncologist</i> , 2013, 18, e18.	1.9	3
258	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	0.8	381
259	Intertumoral and Intratumoral Heterogeneity as a Barrier for Effective Treatment of Medulloblastoma. <i>Neurosurgery</i> , 2013, 60, 57-63.	0.6	13
260	Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment. <i>Oncologist</i> , 2012, 17, 274-278.	1.9	30
261	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	13.7	761
262	Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis. <i>Developmental Medicine and Child Neurology</i> , 2012, 54, 563-568.	1.1	84
263	FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. <i>Cancer Genetics</i> , 2011, 204, 577-588.	0.2	50
264	Rearrangement of Chromosome 14q with Associated White Matter Disease. <i>Pediatric Neurology</i> , 2011, 45, 117-120.	1.0	2
265	An Unusual Presentation of Copper Metabolism Disorder and a Possible Connection With Niemann-Pick Type C. <i>Journal of Child Neurology</i> , 2011, 26, 518-521.	0.7	12
266	Acquired Monocular Nystagmus as the Initial Presenting Sign of a Chiasmal Glioma. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 96-97.	0.3	5
267	Long-Term Survival and Late Onset Seizures in an Adolescent with Trisomy 13. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 694-696.	0.3	3
268	Developmental Disability: Duplication of Zinc Finger Transcription Factors 673 and 674. <i>Pediatric Neurology</i> , 2010, 43, 209-212.	1.0	6
269	Atypical Rett syndrome with selective FOXP1 deletion detected by comparative genomic hybridization: case report and review of literature. <i>European Journal of Human Genetics</i> , 2009, 17, 1577-1581.	1.4	67
270	Systematic Review of Biomarkers of Brain Injury in Term Neonatal Encephalopathy. <i>Pediatric Neurology</i> , 2009, 40, 215-226.	1.0	125

#	ARTICLE	IF	CITATIONS
271	Decompressive Hemicraniectomy in Children With Severe Ischemic Stroke and Life-Threatening Cerebral Edema. <i>Journal of Child Neurology</i> , 2008, 23, 889-894.	0.7	38
272	Vanishing White Matter Disease With Periodic (Paroxysmal) Hemiparesis. <i>Pediatric Neurology</i> , 2006, 35, 65-68.	1.0	11
273	Patterns of brain injury in term neonatal encephalopathy. <i>Journal of Pediatrics</i> , 2005, 146, 453-460.	0.9	487
274	Epilepsia Partialis Continua: Acute Disseminated Encephalomyelitis or Rasmussen's Encephalitis?. <i>Pediatric Neurology</i> , 2005, 32, 341-345.	1.0	6
275	Trends in severe brain injury and neurodevelopmental outcome in premature newborn infants: The role of cystic periventricular leukomalacia. <i>Journal of Pediatrics</i> , 2004, 145, 593-599.	0.9	289
276	Global Control of Histone Modification by the Anaphase-Promoting Complex. <i>Molecular and Cellular Biology</i> , 2003, 23, 9136-9149.	1.1	30
277	The Ubiquitin-Dependent Targeting Pathway in <i>Saccharomyces cerevisiae</i> Plays a Critical Role in Multiple Chromatin Assembly Regulatory Steps. <i>Genetics</i> , 2002, 162, 615-632.	1.2	26
278	Abnormalities of Structural Brain Connectivity in Pediatric Brain Tumor Survivors. <i>Neuro-Oncology Advances</i> , 0, , .	0.4	0
279	How do we approach the management of medulloblastoma in young children?. <i>Pediatric Blood and Cancer</i> , 0, , .	0.8	1